Stock 603566 PULIKE BIOLOGICAL ENGINEERING, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Pulike Biological Engineering, Inc.

Equities

603566

CNE1000025N0

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-28 pm EDT 		5-day change 1st Jan Change
17.43 CNY +1.34% Intraday chart for Pulike Biological Engineering, Inc. -3.43% -23.05%
Apr. 25 Pulike Biological Engineering, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Apr. 25 Pulike Biological Engineering, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • The company's EBITDA/Sales ratio is relatively high and results in high margins before depreciation, amortization and taxes.
  • Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.

Weaknesses

  • With an enterprise value anticipated at 3.52 times the sales for the current fiscal year, the company turns out to be overvalued.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
  • The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
  • The average consensus view of analysts covering the stock has deteriorated over the past four months.
  • Over the past twelve months, analysts' opinions have been revised negatively.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
  • The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Pharmaceuticals

1st Jan change Capi. Investor Rating ESG Refinitiv
PULIKE BIOLOGICAL ENGINEERING, INC. Stock Pulike Biological Engineering, Inc.
-23.05% 805M -
ZOETIS INC. Stock Zoetis Inc.
-19.09% 72.39B
B+
ELANCO ANIMAL HEALTH INCORPORATED Stock Elanco Animal Health Incorporated
-8.93% 6.54B
B-
BLUESTAR ADISSEO COMPANY Stock Bluestar Adisseo Company
+21.38% 3.43B
B-
VIMIAN GROUP AB Stock Vimian Group AB
+1.52% 1.4B -
JINYU BIO-TECHNOLOGY CO., LTD. Stock Jinyu Bio-technology Co., Ltd.
-16.99% 1.34B
B
VETOQUINOL SA Stock Vetoquinol SA
-3.81% 1.26B -
CHINA ANIMAL HUSBANDRY INDUSTRY CO., LTD. Stock China Animal Husbandry Industry Co., Ltd.
-26.05% 1.2B
C-
WUHAN KEQIAN BIOLOGY CO.,LTD Stock Wuhan Keqian Biology Co.,Ltd
-12.71% 1.12B -
TIANJIN RINGPU BIO-TECHNOLOGY CO.,LTD. Stock Tianjin Ringpu Bio-Technology Co.,Ltd.
-4.03% 990M -
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. 603566 Stock
  4. Ratings Pulike Biological Engineering, Inc.